Overview

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)

Status:
Completed
Trial end date:
2019-11-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether in patients with early type 2 diabetes,a short-term intensive metabolic intervention comprising of sitagliptin, metformin, basal insulin glargine and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.
Phase:
Phase 3
Details
Lead Sponsor:
Population Health Research Institute
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc
Metformin
Sitagliptin Phosphate